Profound Medical Corp. (PROF) AI Stock Analysis

Profound Medical Corp. is a medical device company focused on advancing magnetic resonance guided ablation procedures. Operating across Canada, Germany, the United States, and Finland, the company develops therapies for prostate disease, uterine fibroids, and palliative pain management. Its flagship TULSA-PRO system integrates with magnetic resonance imaging scanners in hospitals to provide precise treatment options. The company also offers the Sonalleve platform, a therapeutic solution designed for the non-invasive treatment of uterine fibroids and palliative pain relief for patients with bone metastases. Profound Medical is headquartered in Mississauga, Canada.

Revenue rose from $6.9M in FY2021 to $16.4M in FY2025, supported by a 5-year revenue CAGR of 17.5% from FY2020 to FY2025. Annual top-line growth accelerated to 41.2% in FY2024 and 61.1% in FY2025, alongside gross margin expansion from 43.0% in FY2021 to 70.8% in FY2025. However, net losses widened from -$30.7M in FY2021 to -$43.3M in FY2025, impacted by an operating margin of -256.3% and research and development expenses of $21.0M. For the trailing twelve months ended June 30, 2026, revenue stood at $19.1M, with quarterly revenue growing 12.3% year-over-year and an EPS of -$0.99.

As of June 30, 2026, Profound Medical held $38.3M in cash and short-term investments against $7.3M in total debt, resulting in net cash of $31.0M. Liquidity remains supported by a current ratio of 6.45 and a debt-to-equity ratio of 0.15 on shareholders' equity of $49.8M. Operating cash flow in FY2025 was -$38.9M, and free cash flow was -$39.1M after capital expenditures of $179,084. Dilution occurred over the longer term, with share count increasing 75.0% over 5 years.

Profound Medical trades at a price-to-sales multiple of 11.5x and an enterprise value-to-revenue multiple of 9.4x, based on a market cap of $219.6M and an enterprise value of $179.7M. Its price-to-sales ratio stands above the 4.1x median of its US-listed Healthcare peers. Over the past year, the stock returned 8.1%, trailing the 16.8% return of the S&P 500 (SPY). Over a 5-year period, the stock declined 60.0% compared to an 83.0% gain for the S&P 500.

All 5 analysts covering Profound Medical assign it a Strong Buy rating. The mean price target is $11.14, representing an 85.4% premium over the October 16, 2026 closing price of $6.01. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $37.4M and an EPS of -$0.84. For the following fiscal year, 5 analysts forecast revenue of $60.0M and an EPS of -$0.59. The company beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Profound Medical Corp. (PROF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PROF income statement, PROF balance sheet, PROF key metrics, PROF analyst forecast, PROF chart. See the PROF stock overview for the latest quote and news.